Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Modern treatment of adult short bowel syndrome patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Intraoperative hemodynamic monitoring during liver transplantation: goals and devices

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Repeated Metabolic Balance Studies in Patients With Short Bowel Syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
By definition, intestinal failure prevails when oral compensation is no longer feasible and parenteral support is necessary to maintain nutritional equilibrium. In the past, conventional treatment has mainly focused on "making the most of what the short bowel syndrome patient still had" by optimizing remnant intestinal function through dietary interventions, antidiarrheals and antisecretory agents. However, modern treatment options are in the near horizon, and the increased understanding of the mediators for intestinal adaptation will lead to the expansion of the limited treatment armamentarium in short bowel syndrome patients with intestinal failure. The clinical meaningfulness and implications of the observed effects of growth hormone, glutamine, glucagon-like peptide 2 (GLP-2) and the dipeptidyl peptidase-4 degradation resistant analog, teduglutide, is presented in this review and balanced against treatment related adverse events and possible unfavourable effects of long-term, possibly lifelong, treatments.
OriginalsprogEngelsk
TidsskriftMinerva Gastroenterologica e Dietologica
Vol/bind57
Udgave nummer4
Sider (fra-til)405-17
Antal sider13
ISSN1121-421X
StatusUdgivet - 2011

ID: 33291895